ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02743650
Recruitment Status : Terminated (Difficulties identifying subjects who were qualified to participate in the study)
First Posted : April 19, 2016
Last Update Posted : November 14, 2018
Sponsor:
Collaborator:
The University of Utah Center on Aging
Information provided by (Responsible Party):
Kalani Raphael, University of Utah

Brief Summary:
The goal of this pilot study is to determine whether oral sodium bicarbonate can raise low serum bicarbonate concentration in people without chronic kidney disease (CKD). Participants will take sodium bicarbonate for six weeks, followed by a four week washout period.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Dietary Supplement: Sodium bicarbonate Not Applicable

Detailed Description:

CKD affects 25 million Americans and the risks of cardiovascular morbidity, hospitalizations, and death are substantially higher for people with CKD. Furthermore, 6% of the total Medicare budget is spent on 600,000 people with end-stage renal disease. Thus, CKD is highly prevalent, associates with poor outcomes, and is a tremendous financial burden to society.

Apart from treating hypertension and diabetes, there are no therapies that prevent CKD. However, results from two studies have found that low serum bicarbonate levels increase risk of developing CKD, which suggests that normalizing low serum bicarbonate may prevent CKD.

One way to raise low serum bicarbonate is by taking sodium bicarbonate. Whether sodium bicarbonate, which is commonly prescribed to raise low serum bicarbonate in people with CKD, can raise low bicarbonate in people without CKD is uncertain because the reason bicarbonate is low in people without CKD is unclear. This is because low bicarbonate by itself cannot distinguish whether the acid-base abnormality is primary metabolic acidosis or respiratory alkalosis. The former process is readily corrected with alkali. However, the administration of alkali in the latter situation may not raise bicarbonate concentration.

Therefore, the purpose of this pilot study is to determine whether oral sodium bicarbonate can raise low serum bicarbonate in people without renal disease.

The study is a single-arm open label study of 15 individuals without CKD with low serum bicarbonate concentration. The study duration is 10 weeks. After completing the baseline visit, participants will take oral sodium bicarbonate (initial dose level: 0.3 milliequivalents per kilogram per day (mEq/kg/d) for 6 weeks (On-treatment period), followed by a 4 week Off-treatment period. Serum concentrations of sodium bicarbonate will be tested during the treatment period, at the end of the On-treatment period (Week 6) and at the end of the Off-treatment period (Week 10).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate
Study Start Date : February 2016
Actual Primary Completion Date : June 14, 2017
Actual Study Completion Date : June 14, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Sodium Bicarbonate

All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).

The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening.

Dietary Supplement: Sodium bicarbonate
The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.




Primary Outcome Measures :
  1. Change in serum bicarbonate concentration from baseline to 6 weeks [ Time Frame: Baseline and 6 weeks ]
    Comparison of pre-intervention serum bicarbonate levels to week 6 levels following treatment with oral sodium bicarbonate.


Secondary Outcome Measures :
  1. Change in serum bicarbonate concentration after 4 weeks of stopping sodium bicarbonate treatment [ Time Frame: Baseline, 6 weeks and 10 weeks ]
    Comparison of serum bicarbonate levels four weeks after discontinuing oral sodium bicarbonate treatment to pre-intervention (baseline) and immediate post-treatment (week 6) serum bicarbonate levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2
  • Urinary albumin/creatinine ratio < 30 mg/gm
  • Serum bicarbonate ≤ 23 mEq/L (average of the two most recent measurements within the past year)
  • Age ≥ 50 years

Exclusion Criteria:

  • Blood pressure ≥ 160/100 mm Hg
  • Serum potassium < 3.5 mEq/L
  • New York Heart Association Class 3 or 4 heart failure symptoms
  • Chronic oxygen therapy
  • Chronic obstructive pulmonary disease requiring daily bronchodilator or prednisone therapy
  • Weight ≥ 160 kg
  • Use of sodium bicarbonate, sodium citrate, potassium citrate, or potassium bicarbonate within the previous two weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02743650


Locations
United States, Utah
VA Salt Lake City Healthcare System
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
The University of Utah Center on Aging
Investigators
Principal Investigator: Kalani L Raphael, MD VA Salt Lake City Healthcare System